BiotechTubeBiotechTube
Home/Sionna Therapeutics/Natalie Holles
NH

Natalie Holles

Board Member

Sionna Therapeutics

Roles

Board MemberatSionna Therapeutics
President and Chief Executive Officer, DirectoratThird Harmonic Bio
DirectoratUnity Biotechnology

Therapeutic Areas

Rare DiseasesPulmonary

Sionna Therapeutics Pipeline

DrugIndicationPhase
SION-638Cystic Fibrosis (F508del mutation)Phase 1
SION-109Cystic Fibrosis (F508del mutation)Preclinical
SION-451Cystic Fibrosis (F508del mutation)Preclinical
SION-676Cystic Fibrosis (F508del mutation)Preclinical

Leadership Team at Sionna Therapeutics

MC
Mike Cloonan
President and Chief Executive Officer
CJ
Charlotte Jones
Chief Development Officer
DD
Dr. David Rodman
Chief Medical Officer
DJ
Dr. Jennifer L. Grootenhuis
Chief Scientific Officer
DM
Dr. Martin Mense
Senior Vice President, Biology
DP
Dr. Peter Mueller
Chief Scientific Officer, Strategic Operations
DJ
Dr. Jeffrey M. Keane
Head of Corporate Development
View full Sionna Therapeutics profile